HTA
JAZZ icon

Haber Trilix Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Haber Trilix Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$81K Buy
+1,180
New +$72.1K 0.01% 202

Other funds holding JAZZ

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $5.02B AUM 66.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

Haber Trilix Advisors's JAZZ Position: Q2 2013 in Review

Haber Trilix Advisors opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2013: 1,180 shares worth $81K. The stake represents 0.01% of the portfolio and ranks #202 among its holdings.

234 funds tracked by Wall St. Rank hold JAZZ as of Q2 2013.

  • Haber Trilix Advisors held 1,180 shares of Jazz Pharmaceuticals worth $81K as of Q2 2013.
  • Jazz Pharmaceuticals was a new Haber Trilix Advisors position in Q2 2013.
  • Jazz Pharmaceuticals made up 0.01% of Haber Trilix Advisors's portfolio in Q2 2013, its #202 holding.
  • 234 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2013.

Based on Haber Trilix Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.